DIP
ALNY icon

DT Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

DT Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$3.03K – 557
2024
Q3 		$3.03K Buy
+11
New +$2.86K ﹤0.01% 573
2024
Q2 		– Sell
-5
Closed -$748 – 526
2024
Q1 		$748 Hold
5
– – ﹤0.01% 454
2023
Q4 		$901 Hold
5
– – ﹤0.01% 451
2023
Q3 		$886 Hold
5
– – ﹤0.01% 447
2023
Q2 		$946 Hold
5
– – ﹤0.01% 452
2023
Q1 		$1.01K Hold
5
– – ﹤0.01% 453
2022
Q4 		$1.19K Hold
5
– – ﹤0.01% 472
2022
Q3 		$1K Buy
+5
New +$954 ﹤0.01% 446

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

DT Investment Partners's ALNY Position: Q4 2024 in Review

DT Investment Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 11 shares — an estimated $3.03K sold.

DT Investment Partners first reported a position in ALNY in Q3 2022 and held it in 8 quarters. The position peaked at $3.03K in Q3 2024. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • DT Investment Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • DT Investment Partners sold 11 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $3.03K.
  • DT Investment Partners first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • DT Investment Partners's Alnylam Pharmaceuticals position peaked at $3.03K in Q3 2024.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on DT Investment Partners's 13F filing for Q4 2024, filed 30 Jan 2025.